Cargando…

Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering

Monoclonal antibodies (mAbs) represent a dynamic class of biopharmaceutical products, as evidenced by an increasing number of market authorizations for mAb innovator and biosimilar products. Stability studies are commonly performed during product development, for instance, to exclude unstable molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Legrand, Pauline, Dufaÿ, Sophie, Mignet, Nathalie, Houzé, Pascal, Gahoual, Rabah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709354/
https://www.ncbi.nlm.nih.gov/pubmed/36449030
http://dx.doi.org/10.1007/s00216-022-04396-7
_version_ 1784841133782728704
author Legrand, Pauline
Dufaÿ, Sophie
Mignet, Nathalie
Houzé, Pascal
Gahoual, Rabah
author_facet Legrand, Pauline
Dufaÿ, Sophie
Mignet, Nathalie
Houzé, Pascal
Gahoual, Rabah
author_sort Legrand, Pauline
collection PubMed
description Monoclonal antibodies (mAbs) represent a dynamic class of biopharmaceutical products, as evidenced by an increasing number of market authorizations for mAb innovator and biosimilar products. Stability studies are commonly performed during product development, for instance, to exclude unstable molecules, optimize the formulation or determine the storage limit. Such studies are time-consuming, especially for mAbs, because of their structural complexity which requires multiple analytical techniques to achieve a detailed characterization. We report the implementation of a novel methodology based on the accelerated stability assessment program (ASAP) in order to model the long-term stability of mAbs in relation to different structural aspects. Stability studies of innovator infliximab and two different biosimilars were performed using forced degradation conditions alongside in-use administration conditions in order to investigate their similarity regarding stability. Thus, characterization of post-translational modifications was achieved using liquid-chromatography–tandem mass spectrometry (LC-MS/MS) analysis, and the formation of aggregates and free chain fragments was characterized using size-exclusion chromatography–multi-angle light scattering (SEC-MALS-UV/RI) analysis. Consequently, ASAP models were investigated with regard to free chain fragmentation of mAbs concomitantly with N57 deamidation, located in the hypervariable region. Comparison of ASAP models and the long-term stability data from samples stored in intravenous bags demonstrated a relevant correlation, indicating the stability of the mAbs. The developed methodology highlighted the particularities of ASAP modeling for mAbs and demonstrated the possibility to independently consider the different types of degradation pathways in order to provide accurate and appropriate prediction of the long-term stability of this type of biomolecule. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-022-04396-7.
format Online
Article
Text
id pubmed-9709354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97093542022-11-30 Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering Legrand, Pauline Dufaÿ, Sophie Mignet, Nathalie Houzé, Pascal Gahoual, Rabah Anal Bioanal Chem Research Paper Monoclonal antibodies (mAbs) represent a dynamic class of biopharmaceutical products, as evidenced by an increasing number of market authorizations for mAb innovator and biosimilar products. Stability studies are commonly performed during product development, for instance, to exclude unstable molecules, optimize the formulation or determine the storage limit. Such studies are time-consuming, especially for mAbs, because of their structural complexity which requires multiple analytical techniques to achieve a detailed characterization. We report the implementation of a novel methodology based on the accelerated stability assessment program (ASAP) in order to model the long-term stability of mAbs in relation to different structural aspects. Stability studies of innovator infliximab and two different biosimilars were performed using forced degradation conditions alongside in-use administration conditions in order to investigate their similarity regarding stability. Thus, characterization of post-translational modifications was achieved using liquid-chromatography–tandem mass spectrometry (LC-MS/MS) analysis, and the formation of aggregates and free chain fragments was characterized using size-exclusion chromatography–multi-angle light scattering (SEC-MALS-UV/RI) analysis. Consequently, ASAP models were investigated with regard to free chain fragmentation of mAbs concomitantly with N57 deamidation, located in the hypervariable region. Comparison of ASAP models and the long-term stability data from samples stored in intravenous bags demonstrated a relevant correlation, indicating the stability of the mAbs. The developed methodology highlighted the particularities of ASAP modeling for mAbs and demonstrated the possibility to independently consider the different types of degradation pathways in order to provide accurate and appropriate prediction of the long-term stability of this type of biomolecule. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-022-04396-7. Springer Berlin Heidelberg 2022-11-30 2023 /pmc/articles/PMC9709354/ /pubmed/36449030 http://dx.doi.org/10.1007/s00216-022-04396-7 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research Paper
Legrand, Pauline
Dufaÿ, Sophie
Mignet, Nathalie
Houzé, Pascal
Gahoual, Rabah
Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title_full Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title_fullStr Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title_full_unstemmed Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title_short Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
title_sort modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709354/
https://www.ncbi.nlm.nih.gov/pubmed/36449030
http://dx.doi.org/10.1007/s00216-022-04396-7
work_keys_str_mv AT legrandpauline modelingstudyoflongtermstabilityofthemonoclonalantibodyinfliximabandbiosimilarsusingliquidchromatographytandemmassspectrometryandsizeexclusionchromatographymultianglelightscattering
AT dufaysophie modelingstudyoflongtermstabilityofthemonoclonalantibodyinfliximabandbiosimilarsusingliquidchromatographytandemmassspectrometryandsizeexclusionchromatographymultianglelightscattering
AT mignetnathalie modelingstudyoflongtermstabilityofthemonoclonalantibodyinfliximabandbiosimilarsusingliquidchromatographytandemmassspectrometryandsizeexclusionchromatographymultianglelightscattering
AT houzepascal modelingstudyoflongtermstabilityofthemonoclonalantibodyinfliximabandbiosimilarsusingliquidchromatographytandemmassspectrometryandsizeexclusionchromatographymultianglelightscattering
AT gahoualrabah modelingstudyoflongtermstabilityofthemonoclonalantibodyinfliximabandbiosimilarsusingliquidchromatographytandemmassspectrometryandsizeexclusionchromatographymultianglelightscattering